KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial.

Peter A Fasching, Daniil Stroyakovskiy, Denise A Yardley, Chiun-Sheng Huang, John Crown, Aditya Bardia, Stephen Chia, Seock-Ah Im, Miguel Martin, Binghe Xu, Sherene Loi, Carlos Barrios, Michael Untch, Rebecca Moroose, Frances Visco, Gabriel N Hortobagyi, Dennis J Slamon, Rodrigo Fresco, Juan Pablo Zarate, Zheng Li, Sorcha Waters, Sara A Hurvitz

JAMA Oncol 11(11) 1364-1372

PMID40996773
PMCIDPMC12464853
DOI10.1001/jamaoncol.2025.3700
发表日期2025-09-25
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

IMPORTANCE: Ribociclib plus a nonsteroidal aromatase inhibitor (NSAI) has demonstrated a statistically significant invasive disease-free survival (iDFS) benefit over NSAI alone in patients with hormone receptor-positive/ERBB2 (formerly HER2)-negative early breast cancer. Evaluating the efficacy and safety of adjuvant ribociclib beyond the planned 3-year treatment period is critical for understanding the long-term impact on recurrences. OBJECTIVE: To evaluate efficacy and safety of adjuvant ribociclib in an exploratory 4-year analysis of the NATALEE (New Adjuvant Trial With Ribociclib [LEE011]) randomized clinical trial, with all patients no longer receiving ribociclib treatment. DESIGN, SETTING, AND PARTICIPANTS: This exploratory analysis of an international, open-label, randomized phase 3 trial analyzed adjuvant treatment for premenopausal and postmenopausal women and men with hormone receptor-positive/ERBB2-negative early breast cancer. Eligible patients had anatomic stage IIA (either N0 with additional risk factors or N1 [1-3 axillary lymph nodes]), IIB, or III disease per the American Joint Committee on Cancer Staging Manual, eighth edition. The data cutoff date was April 29, 2024. INTERVENTIONS: Patients were randomized 1:1 to receive ribociclib (400 mg once daily, days 1-21 of a 28-day cycle, over 36 months) plus NSAI (letrozole, 2.5 mg, or anastrozole, 1 mg, once daily continuously for 60 months) or NSAI alone. Men and premenopausal women also received goserelin (3.6 mg once every 28 days administered subcutaneously). MAIN OUTCOMES AND MEASURES: The primary end point was iDFS, and secondary efficacy end points included distant disease-free survival, recurrence-free survival, and overall survival. Survival was evaluated by the Kaplan-Meier method. RESULTS: Among 5101 patients included in the analysis (median [range] age, 52 [24-90] years; 5081 [99.6%] female), the median follow-up for iDFS was 44.2 months (range, 0-63 months). Ribociclib plus NSAI continued to show iDFS benefit over NSAI alone (hazard ratio, 0.72; 95% CI, 0.61-0.84), with 3-year iDFS rates of 90.8% vs 88.1% (difference, 2.7 percentage points) and 4-year rates of 88.5% vs 83.6% (difference, 4.9 percentage points). The efficacy benefit was consistent across subgroups and secondary end points. Overall survival data remain immature, although a trend in favor of ribociclib plus NSAI over NSAI alone was observed (hazard ratio, 0.83; 95% CI, 0.64-1.07). The incidence of adverse events has remained stable. CONCLUSIONS AND RELEVANCE: This exploratory analysis of the NATALEE randomized clinical trial, with a median follow-up beyond the 3-year treatment duration, demonstrated consistent iDFS benefit with ribociclib plus NSAI over NSAI alone. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03701334.

KM 提取结果

2 个 Figure · 5 个 KM 面板

进入结果中心
KM Figure1 个面板

Figure 1

Figure 1.. Invasive Disease-Free Survival in the Intent-to-Treat Population The dashed lines at 36 and 48 months represent the planned 3-year treatment duration and 4-year exploratory treatment analysis, respectively. NSAI indicates nonsteroidal aromatase inhibitor.

Invasive_Disease-Free_Survival_in_the_Intent-to-Treat_Population

Invasive disease-free survival

Figure 1 · Panel Invasive_Disease-Free_Survival_in_the_Intent-to-Treat_Population

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Invasive_Disease-Free_Survival_in_the_Intent-to-Treat_Population 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:short span
查看结果
KM Figure4 个面板

Figure 3

Figure 3.. Survival Outcomes in the Intent-to-Treat Population The dashed lines at 36 and 48 months represent the planned 3-year treatment duration and 4-year exploratory treatment analysis, respectively. DDFS indicates distant disease-free survival; DRFS, distant recurrence-free survival; NSAI, nonsteroidal aromatase inhibitor; OS, overall survival; RFS, recurrence-free survival.

A

DDFS

Figure 3 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

RFS

Figure 3 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
C

DRFS

Figure 3 · Panel C

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel C 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
D

OS

Figure 3 · Panel D

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel D 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似图例或人工水平线:轨迹出现不合理的共同平台疑似图例或人工水平线:轨迹出现不合理的共同平台曲线 1:flat topline artifact
查看结果
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 2Figure 2.. Forest Plot of Invasive Disease-Free Survival (iDFS) Across Clinically Relevant Subgroups AJCC indicates the American Joint Committee on Cancer Staging Manual, eighth edition ; NSAI, nonsteroidal aromatase inhibitor. a From archival tumor tissue. b Nodal status classification according to AJCC staging. c Nodal status is from the worst stage derived per surgical specimen or at diagnosis.
非 KM Figure